- Home
- GNPX vs JXG Comparison
GNPX vs JXG Comparison
Compare GNPX & JXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- JXG
- Stock Information
- Founded
- GNPX 2009
- JXG N/A
- Country
- GNPX United States
- JXG China
- Employees
- GNPX N/A
- JXG N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- JXG
- Sector
- GNPX Health Care
- JXG
- Exchange
- GNPX Nasdaq
- JXG Nasdaq
- Market Cap
- GNPX 7.0M
- JXG N/A
- IPO Year
- GNPX 2018
- JXG N/A
- Fundamental
- Price
- GNPX $0.29
- JXG $2.44
- Analyst Decision
- GNPX Strong Buy
- JXG
- Analyst Count
- GNPX 1
- JXG 0
- Target Price
- GNPX $10.00
- JXG N/A
- AVG Volume (30 Days)
- GNPX 2.6M
- JXG 75.2K
- Earning Date
- GNPX 05-16-2025
- JXG 05-19-2025
- Dividend Yield
- GNPX N/A
- JXG N/A
- EPS Growth
- GNPX N/A
- JXG N/A
- EPS
- GNPX N/A
- JXG 2.20
- Revenue
- GNPX N/A
- JXG $38,490,872.00
- Revenue This Year
- GNPX N/A
- JXG N/A
- Revenue Next Year
- GNPX N/A
- JXG N/A
- P/E Ratio
- GNPX N/A
- JXG $1.10
- Revenue Growth
- GNPX N/A
- JXG N/A
- 52 Week Low
- GNPX $0.22
- JXG $0.75
- 52 Week High
- GNPX $4.09
- JXG $4.92
- Technical
- Relative Strength Index (RSI)
- GNPX 48.94
- JXG N/A
- Support Level
- GNPX $0.27
- JXG N/A
- Resistance Level
- GNPX $0.36
- JXG N/A
- Average True Range (ATR)
- GNPX 0.03
- JXG 0.00
- MACD
- GNPX 0.01
- JXG 0.00
- Stochastic Oscillator
- GNPX 47.45
- JXG 0.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.